Project Grant HT94252510806
Award Date
9/30/25
Completion Date
9/29/29
Dollars Obligated
$4.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The Defense Health Agency awarded a $5,339,958 Project Grant to the Beckman Research Institute of the City of Hope under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the development of a digital health intervention for self-management and telemonitoring in chimeric antigen receptor (CAR)-T cell therapy. This 4-year research project, running from June 2025 to June 2029, aims to advance medical solutions for the battlefield and transform healthcare for...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
The federal Project Grant award of $4,029,612 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the "INFLUENCE TRIAL: IMPROVING EVENT-FREE SURVIVAL BY OPTIMIZING FLUDARABINE EXPOSURE DURING LYMPHODEPLETION FOR CAR T CELL THERAPY" at the Sloan-Kettering Institute for Cancer Research in New York. This grant aims to optimize fludarabine exposure during lymphodepletion to improve event-free survival for patients receiving CAR T-cell...
This $240,897 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will support integrative transcriptomic and epigenomic profiling of subependymal giant cell astrocytoma at single-cell resolution. The award was made to Duke University's Office of Research Administration on August 1, 2025, with a period of performance through July 31, 2027. The Military Medical Research and Development program funds advanced biomedical...
This federal Project Grant award of $613,125.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of Texas MD Anderson Cancer Center to develop EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative...
The U.S. Department of Defense's Defense Health Agency awarded a $845,250 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Duke University. The grant, with a performance period from July 1, 2025 to June 30, 2028, will fund research to engineer TCR-T cells to target human endogenous retroviruses for non-small cell lung cancer immunotherapy. The goal of this advanced biomedical research is to transform healthcare for military service members, veterans, and...
This $1,599,997.00 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of Illinois aimed at transforming healthcare for military service members, veterans, and the broader public. The research, spanning basic, applied, and translational investigations, focuses on innovative approaches to address critical health challenges across diverse medical domains such as cancer,...
This Project Grant award of $154,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Regents of the University of Minnesota to develop a dual-targeting G/D CAR-T cell therapy for the treatment of rhabdomyosarcoma. The award period runs from September 1, 2025 to August 31, 2027. The University of Minnesota, a prominent land-grant research institution, will leverage its extensive medical research capabilities to...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...